Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Cellectar said a heavily pretreated DLBCL patient had a complete response lasting over eight years after one iopofosine I 131 administration. The company expects to begin dosing its confirmatory Phase 3 WM study in Q1 2027 and targets an H1 2027 FDA filing.
The company reported a case study describing a complete response lasting more than eight years in a heavily pretreated DLBCL patient treated with iopofosine I 131.